After decades of repeatedly negative clinical trial results, more than hope is emerging for ALS patients. Indeed, data from the VALOR study, a phase III clinical trial of tofersen in… More >>

– FDA Advisory Committee voted 7:2 that the available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS – If approved, AMX0035 will be the… More >>

AB Science announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS).… More >>

Dear ALS Community, We are writing to let you know that Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Biogen’s New Drug Application for tofersen, an investigational drug… More >>

Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022 Cytokinetics announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv on ALSFRS-R… More >>

Today Amylyx announced that Health Canada has approved ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). Clinical data demonstrated a statistically significant and… More >>

• 12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life • Tofersen also led to robust and sustained reductions… More >>

TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties Tranquis plans to start a Phase 2 trial in ALS by the end of 2022 Tranquis Therapeutics, a clinical stage immuno-neurology… More >>